A novel logical model of COVID-19 intracellular infection to support therapies development

Elena Piretto1, Gianluca Selvaggio2, Damiano Bragantini3

  • 1European Institute of Oncology IRCCS, Milan, Italy.

Insights

This study models COVID-19 cellular pathways to test drug treatments. Combining Baricitinib, Remdesivir, and Dexamethasone shows the most promising results for effective COVID-19 treatment strategies.

Area of Science:

  • Computational biology
  • Infectious disease modeling
  • Pharmacology

Background:

  • COVID-19 infection involves complex cellular pathways.
  • Understanding drug mechanisms is crucial for effective treatment.
  • Mathematical modeling offers a platform to study these interactions.

Purpose of the Study:

  • To develop a logical-based mathematical model of COVID-19 cellular pathways.
  • To simulate and evaluate various drug treatments (single and combination).
  • To analyze drug mechanisms and their impact on molecular pathways.

Main Methods:

  • Development of a logical-based mathematical model.
  • In silico simulation of drug treatments.
  • Sensitivity analysis of model parameters.
  • Analysis of drug mechanisms on molecular pathways.

Main Results:

  • Single drug treatments showed limited or scenario-dependent effects.
  • Combination therapies yielded better outcomes than monotherapies.
  • A triple combination of Baricitinib, Remdesivir, and Dexamethasone demonstrated significant efficacy.
  • The study identified specific molecular pathway impacts for each drug.

Conclusions:

  • Mathematical modeling is valuable for predicting COVID-19 treatment efficacy.
  • Combination drug therapy, particularly Baricitinib, Remdesivir, and Dexamethasone, is a promising strategy.
  • Understanding drug-specific mechanisms enhances therapeutic development for COVID-19.